The Asia Pacific diabetic retinopathy market is projected to grow from USD 2.02 billion in 2025 to around USD 4.28 billion by 2035, expanding at a CAGR of 7.80%. Growth is driven by rising diabetes prevalence, increasing awareness of eye health, and advancements in retinal imaging and treatment technologies.

Asia Pacific Diabetic Retinopathy Market Statical Scope

More than half of the global population living in Asia, particularly in China and India, is dealing with obesity, diabetes, and insulin resistance. Research suggests that the most causative factors of visual impairment in Asia are cataracts and refractive error. The International Agency for the Prevention of Blindness (IAPB) established a South-East Asia Diabetic Retinopathy Expert Group to strengthen the diagnosis and treatment of diabetic retinopathy in the South-East Asia region.

Asia Pacific Diabetic Retinopathy Market Share, By Type, 2025 (%)

• Non-proliferative Diabetic Retinopathy (NPDR)- The non-proliferative diabetic retinopathy segment dominates with a share of 72%, owing to the shift towards annual comprehensive eye exams that are essential for all diabetics.
• Proliferative Diabetic Retinopathy (PDR)- The proliferative diabetic retinopathy segment holds a share of 28%, due to effective management and treatment to prevent progression of PDR.

Asia Pacific Diabetic Retinopathy Market Share, By Management, 2025 (%)

• Anti-VEGF- The anti-VEGF segment is seen to hold a share of 56%, driven by the need for consistent, chronic, and frequent follow-ups.
• Laser Surgery- The laser surgery segment is observed to expand with a share of 18%, supported by the preference for Panretinal Photocoagulation (PRP) or focal/grid laser to reduce macular edema and shrink abnormal blood vessels.
• Intraocular Steroid Injection- The intraocular steroid injection segment drives a share of 14%, accelerated by the potential of such targeted treatments to reduce inflammation and macular swelling more effectively for chronic conditions.
• Vitrectomy- The vitrectomy segment occupies a share of 12%, because this surgical procedure allows specialists to treat diabetic retinopathy, retinal detachment, eye injuries, and macular holes.

Top Companies in the Asia Pacific Diabetic Retinopathy Market

• Bayer AG
• AbbVie Inc.
• Novartis AG
• Oxurion NV.
• Sirnaomics
• Alimera Sciences
• Ampio Pharmaceuticals Inc.
• BCNPeptides
• Kowa Company, Ltd.
• Genentech, Inc.

Segments Covered in the Report

By Type

• Proliferative Diabetic Retinopathy
• Non-proliferative Diabetic Retinopathy

By Management

• Anti-VEGF
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy